All news

A Hungarian fund manager reports a stake above 5% in Protalix BioTherapeutics (PLX).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

HOLD Alapkezelo Zrt., a Hungarian investment fund management company, has reported a beneficial ownership stake of 5.2% in Protalix BioTherapeutics, Inc. (PLX). This stake, amounting to 4,157,791 shares, was measured against 80,571,642 common shares outstanding as of June 30, 2026. The filing indicates that HOLD Alapkezelo Zrt. holds sole voting and dispositive power over these shares.

Read original source

PLX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.